Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27175419
Abstract: Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibitors, are first-line therapies for advanced… read more here.
Keywords: sorafenib lenvatinib; lenvatinib rats; canagliflozin sorafenib; lenvatinib ... See more keywords